Acute profound thrombocytopenia after c7E3 Fab (Abciximab) therapy

Circulation

Volumn 95, Issue 4, 1997, Pages 809-813

  Berkowitz, Scott D ^a   Harrington, Robert A ^a   Rund, Michele M ^a   Tcheng, James E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

abciximab; angioplasty; glycoproteins; platelets; thrombocytopenia

Indexed keywords

ABCIXIMAB;

ADULT; ARTICLE; BLEEDING; CASE REPORT; CORONARY ARTERY OBSTRUCTION; DRUG EFFECT; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; PRIORITY JOURNAL; RESTENOSIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0031055038     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.4.809     Document Type: Article

References (25)

1. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
2. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994;343:881-886.
3. Coller BS. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation. 1995;92:2373-2380.
4. Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation. 1994; 90:1757-1764.
5. Cola C, Ansell J. Heparin-induced thrombocytopenia and arterial thrombosis: alternative therapies. Am Heart J. 1990;119:368-374.
6. Schmitt BP, Adelman B. Heparin-associated thrombocytopenia: a critical review and pooled analysis. Am J Med Sci. 1993;305: 208-215.
7. Greinacher A. Antigen generation in heparin-associated thrombocytopenia: the nonimmunologic type and the immunologic type are closely linked in their pathogenesis. Semin Thromb Hemost, 1995; 21:106-116.
8. Chong BH. Heparin-induced thrombocytopenia. Aust N Z J Med. 1992;22:145-152.
9. Aster RH. Heparin-induced thrombocytopenia. N Engl J Med. 1995;332:1374-1376.
10. Kelton JG, Sheridan D, Brain H, Powers PJ, Turpie AG, Carter CJ. Clinical usefulness of testing for a heparin-dependent platelet-aggregating factor in patients with suspected heparin-associated thrombocytopenia. J Lab Clin Med. 1984;103:606-612.
11. Stricker H, Lammle B, Furlan M, Sulzer I. Heparin-dependent in vitro aggregation of normal platelets by plasma of a patient with heparin-induced skin necrosis: specific diagnostic test for a rare side effect. Am J Med. 1988;85:721-724.
12. Mak K-H, Kottke-Marchant K, Brooks LM, Apheart KL, Topol EJ. Potential value of platelet GPIIb/IIIa antagonist for treating heparin-induced thrombocytopenia. J Am Coll Cardiol. 1996;27:316A.
13. Fareed J, Yang L, Hoppensteadt D, Koza M, Walenga JM, Welzel D. Glycoprotein IIb/IIIa inhibitors can prevent heparin mediated platelet activation in heparin-induced thrombocytopenia. Circulation. 1996;94(Suppl I):I-228. Abstract.
14. Kaplan AV, Leung LL-K, Leung W-H, Grant GW, McDougall IR, Fischell TA. Roles of thrombin and platelet membrane glycoprotein IIb/IIIa in platelet-subendothelial deposition after angioplasty in an ex vivo whole artery model. Circulation. 1991; 84:1279-1288.
15. Turner NA, Moake JL, Kamat SG, Schafer AI, Kleiman NS, Jordan R, McIntire LV. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa. Circulation. 1995;91:1354-1362.
16. Beutler E. Platelet transfusions: the 20,000/μL trigger. Blood. 1993:81:1411-1413.
17. Patten E. Controversies in transfusion medicine: prophylactic platelet transfusion revisited after 25 years - con. Transfusion. 1992;32: 381-385.
18. Gmur J, Burger J, Schanz U, Fehr J, Schaffner A. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet. 1991:338:1223-1226.
19. Lee EJ. Indications for platelet transfusion therapy. In: Kurtz SR, Brubaker DB, eds. Clinical Decisions in Platelet Therapy. Bethesda, Md: American Association of Blood Banks; 1992:31-43.
20. Murphy S. A critical view of prophylactic platelet transfusion. In: Kurtz SR, Brubaker DB, eds. Clinical Decisions in Platelet Therapy. Bethesda, Md: American Association of Blood Banks; 1992:45-54.
21. Gaydos LA, Freireich EJ, Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med. 1962:266:905-909.
22. Bednar B, Bednar RA, Cook JJ, Bollag DM, Chang CT, Gaul SL, McQueney PA, Egbertson MS, Hartman GD, Holahan MA, Lynch JJ, Gould RJ. Drug-dependent antibodies against GPIIb/IIIa induce thrombocytopenia. Circulation. 1996;94(suppl I):I-98. Abstract.
23. Coller BS, Scudder LE, Beer J, Gold HK, Foils JD, Cavagnaro J, Jordan R, Wagner C, Iuliucci J, Knight D, Ghrayeb J, Smith C, Weisman H, Berger H. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann N Y Acad Sci. 1991:614:193-213.
24. Simoons ML, de Boer MJ, van den Brand MJ, van Miltenburg AJ, Hoorntje JC, Heyndrickx GR, van der Wieken LR, de Bono D, Rutsch W, Schaible TF, Weisman HF, Klootwijk P, Nijssen KM, Stibbe J, de Feyter PJ, and the European Cooperative Study Group. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation. 1994:89:596-603.
25. Faulds D, Sorkin EM. Abciximab (c7E3 Fab): a review of its pharmacology and therapeutic potential in ischemic heart disease. Drugs. 1994:48:583-598.